Ethacrynic Acid NDC 69238-1126

NDC codes

FDA NDC Directory

Product NDC (as listed)69238-1126Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69238-1126Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69238-1126-1	69238112601	100 TABLET in 1 BOTTLE (69238-1126-1)Marketed from May 14, 2018

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ethacrynic Acid
Generic name (nonproprietary): ethacrynic acid
Active ingredients: Ethacrynic acid — 25 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Amneal Pharmaceuticals NY LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208805
Marketing start: May 14, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Increased Diuresis at Loop of Henle (Physiologic effect)
Identifiers: Product ID 69238-1126_21b6de3e-2431-4f0c-8440-0ac914ce3d9eSPL ID 21b6de3e-2431-4f0c-8440-0ac914ce3d9eSPL set ID b9bc3907-bfa7-4d9f-90d9-c2097230f7e4RxCUI 1251903UNII M5DP350VZV
Pharmacologic class: Loop Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469238112601 followed by a unit qualifier and the quantity

Package 69238-1126-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 14, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Ethacrynic acid tablets are indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. Intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)